NEW YORK, Oct. 13 /PRNewswire-FirstCall/ -- To accelerate the search
for new and innovative technologies and products that will play a critical
role in its long-term growth, Pfizer today announced the promotion of
Edmund P. Harrigan, M.D. to senior vice president of Worldwide Licensing
and Business Development.
    The Group will have overall responsibility for co-promotion and
licensing agreements, venture capital investments in new technologies and
the acquisition of promising new products and services from outside the
company.
    "While Pfizer's core scientific capabilities are outstanding, the
explosion in medical science and related technologies around the world
means that we now have many more opportunities for strategic investments,"
said David Shedlarz, vice chairman of Pfizer. "Worldwide Licensing and
Business Development brings together previously separate functions so that
all the capabilities and resources necessary to evaluate and secure these
opportunities are in one place, with a clear strategy and accountability.
    "Ed brings deep experience in medicine, clinical development and
regulatory affairs to his new assignment, and I am confident we'll move
quickly on the right opportunities while maintaining a disciplined
investment approach."
    Areas of focus for the Worldwide Licensing and Business Development
Group include:
    -- Entering into co-promotion and licensing agreements;
    -- Investing in new technologies to add value to our core product
       offerings; and
    -- Acquiring new products and services from outside the company.
    Dr. Harrigan has served as Senior Vice President of Worldwide
Regulatory Affairs and Quality Assurance at Pfizer since 2003.
    A board certified neurologist, Dr. Harrigan first joined Pfizer in 1992
and spent nine years in Phase II and III Clinical Development trials
related to the central nervous system. During this time, he obtained
wide-ranging experience in the development of early- and late-stage
candidates, at team and management levels. He led a team in achieving the
approval of Pfizer's new generation antipsychotic medicine Geodon.
    Between 2001 and 2003, Dr. Harrigan was Senior Vice President of
Medical Operations at Sepracor and later moved to Neurogen Corporation as
Executive Vice President and Chief Development Officer. In 2003, he
returned to Pfizer as Vice President, Worldwide Medical Neuroscience and
Ophthalmology, where he focused on marketed drugs and late-stage
development candidates in those therapeutic areas.
    Dr. Harrigan holds a bachelor's degree in Chemistry from St. Anselm
College in New Hampshire and a doctorate in medicine from the University of
Massachusetts at Worcester, where he received his medical degree. He also
attended the Brain Research Institute at the University of California, Los
Angeles.
    More information on Pfizer Inc can be found at http://www.pfizer.com.

Link to this page:

  

http://www.prnewswire.com/comp/688250.html/
CONTACT:
Andy McCormick, +1-212-733-5469; Paul
Fitzhenry, +1-212-733-4637

---

---

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996- PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.